The results revealed a 1- and 2-year cumulative incidence of HCC recurrence of 8.0% and 15.7%, respectively, for patients with high LC3 expression in both tumor and ANT tissues (+/+). This evidence concerns the gene MAP1LC3A and hepatocellular carcinoma.